{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:39:38Z","timestamp":1791725978377,"version":"4.3.4"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"name":"Leumit Health Services","award":["Internally funded"],"award-info":[{"award-number":["Internally funded"]}]},{"name":"National Institute of Health, National Cancer Institute","award":["Intramural Research Program"],"award-info":[{"award-number":["Intramural Research Program"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proton pump inhibitors (PPIs) are widely used for acid-related disorders, but observational studies have raised concerns about a possible association between long-term PPI use and upper gastrointestinal (GI) cancers. These associations may reflect confounding by indication and reverse causation. We aimed to evaluate the association between PPI use and upper GI cancer while explicitly addressing these biases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We conducted a matched case-control study using electronic health records from a national health organization in Israel. Cases were 875 adults (age 63.0\u2009\u00b1\u200911.9 years, 62.5% male) with incident upper GI cancer (esophageal, gastric, or duodenal) diagnosed between 2003 and 2024; each case was matched to 10 cancer-free controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098,750). Matching was performed on age, sex, ethnic sector (general, Jewish ultra-orthodox, and Arab), socioeconomic status, and year of enrollment. PPI exposure was ascertained from pharmacy records and modeled in discrete pre-diagnosis windows (0\u20136 months, 6\u201312 months, 1\u20133 years, and 3\u201310 years). Multivariable conditional logistic regression estimated adjusted odds ratios (aORs) and confidence intervals (CIs), with covariates including age, smoking, body mass index, socioeconomic status, healthcare utilization, pregnancy history (in women), alcohol use,\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      diagnosis, and upper GI symptom-related diagnoses (e.g., gastroesophageal reflux, gastritis, peptic ulcer disease).\n                    <\/jats:p>\n                    <jats:p>\n                      In models without adjustment for symptom-related diagnoses, PPI use was associated with increased odds of cancer (e.g., esomeprazole aOR 4.01, 95% CI 3.20, 5.03,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; omeprazole aOR 2.38, 95% CI 1.99, 2.85,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). When exposure was modeled by time window, associations diminished for exposures &gt;1 year before diagnosis. After excluding the final year before diagnosis and adjusting for symptom-related diagnoses, we did not detect a harmful association between PPI use and upper GI cancer. Remote use (&gt;3 years) was instead associated with lower odds (e.g., omeprazole aOR 0.62, 95% CI 0.51, 0.75,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with similar patterns in a gastric-only subgroup (701 cases, 7,010 controls). Key limitations include potential residual confounding, lack of direct dietary and family-history data, and incomplete capture of over-the-counter PPI use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Apparent harmful associations between PPI use and upper GI cancer were concentrated in the months immediately preceding diagnosis and disappeared after adjusting for diagnostic context and excluding the final year before diagnosis. In these adjusted analyses, we found no evidence of increased odds with long-term PPI use, and remote use (&gt;3 years before diagnosis) was associated with reduced cancer odds for omeprazole and lansoprazole. These findings underscore the importance of investigating new-onset upper GI symptoms rather than attributing malignancy risk to acid-suppressive therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004842","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T18:23:41Z","timestamp":1767723821000},"page":"e1004842","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association between proton pump inhibitor use and upper gastrointestinal cancer: A matched case-control study accounting for reverse causation and confounding by indication"],"prefix":"10.1371","volume":"23","author":[{"given":"Ibrahim O.","family":"Sawaid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohar","family":"Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Golan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan","family":"Ruppin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avivit","family":"Golan-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Merzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Vinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7436-3515","authenticated-orcid":true,"given":"Abraham O.","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4389-8896","authenticated-orcid":true,"given":"Ariel","family":"Israel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"4","key":"pmed.1004842.ref001","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the american gastroenterological association","volume":"152","author":"DE Freedberg","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"pmed.1004842.ref002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 Years of proton pump inhibitors: a comprehensive review","volume":"11","author":"DS Strand","year":"2017","journal-title":"Gut Liver"},{"key":"pmed.1004842.ref003","article-title":"Pharmacology of H2-receptor antagonists: an overview","author":"W Schunack","year":"1989","journal-title":"J Int Med Res"},{"issue":"6","key":"pmed.1004842.ref004","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of proton pump inhibitors","volume":"10","author":"JM Shin","year":"2008","journal-title":"Curr Gastroenterol Rep"},{"issue":"4","key":"pmed.1004842.ref005","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/jamainternmed.2013.14673","article-title":"Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit","volume":"174","author":"R MacLaren","year":"2014","journal-title":"JAMA Intern Med"},{"key":"pmed.1004842.ref006","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.chest.2018.05.015","article-title":"Comparative effectiveness of proton pump inhibitors vs histamine type 2 receptor blockers for preventing clinically important gastrointestinal bleeding during intensive care","volume":"154","author":"CM Lilly","year":"2018","journal-title":"Chest"},{"issue":"10","key":"pmed.1004842.ref007","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1681\/ASN.2015121377","article-title":"Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD","volume":"27","author":"Y Xie","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"14","key":"pmed.1004842.ref008","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14796678.2024.2412910","article-title":"Proton pump inhibitors and cardiovascular risk: a critical review","volume":"20","author":"GJ Duarte","year":"2024","journal-title":"Future Cardiol"},{"issue":"4","key":"pmed.1004842.ref009","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","article-title":"Use of proton pump inhibitors and risk of osteoporosis-related fractures","volume":"179","author":"LE Targownik","year":"2008","journal-title":"CMAJ"},{"issue":"9","key":"pmed.1004842.ref010","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/archinte.167.9.950","article-title":"Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study","volume":"167","author":"SE Gulmez","year":"2007","journal-title":"Arch Intern Med"},{"issue":"4","key":"pmed.1004842.ref011","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis","volume":"73","author":"W Gomm","year":"2016","journal-title":"JAMA Neurol"},{"issue":"1","key":"pmed.1004842.ref012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/gutjnl-2021-325097","article-title":"Proton pump inhibitors and risk of gastric cancer: population-based cohort study","volume":"71","author":"D Abrahami","year":"2021","journal-title":"Gut"},{"key":"pmed.1004842.ref013","doi-asserted-by":"crossref","first-page":"1756284819834511","DOI":"10.1177\/1756284819834511","article-title":"Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence","volume":"12","author":"KS Cheung","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"issue":"17","key":"pmed.1004842.ref014","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3748\/wjg.v25.i17.2058","article-title":"Proton pump inhibitor: the dual role in gastric cancer","volume":"25","author":"MK Joo","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"1","key":"pmed.1004842.ref015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10147-022-02253-2","article-title":"Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review and meta-analysis","volume":"28","author":"T-R Peng","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"pmed.1004842.ref016","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/00365521.2018.1450442","article-title":"Proton pump inhibitors (PPIs) may cause gastric cancer\u2013clinical consequences","volume":"53","author":"HL Waldum","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"pmed.1004842.ref017","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211051463","article-title":"Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis","volume":"14","author":"D Segna","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"pmed.1004842.ref018","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14740338.2016.1118050","article-title":"Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms","volume":"15","author":"Y Ko","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"pmed.1004842.ref019","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1038\/s41467-024-48007-8","article-title":"Individualized prevention of proton pump inhibitor related adverse events by risk stratification","volume":"15","author":"B Xia","year":"2024","journal-title":"Nat Commun"},{"issue":"28","key":"pmed.1004842.ref020","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000043053","article-title":"A meta-analysis of the effects of proton pump inhibitors on the risk of gastric cancer","volume":"104","author":"H Zhang","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"pmed.1004842.ref021","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","article-title":"Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study","volume":"67","author":"KS Cheung","year":"2018","journal-title":"Gut"},{"key":"pmed.1004842.ref022","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.regpep.2007.09.002","article-title":"Hypergastrinemia increases gastric epithelial susceptibility to apoptosis","volume":"146","author":"SMC Przemeck","year":"2008","journal-title":"Regul Pept"},{"issue":"5","key":"pmed.1004842.ref023","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"F Imhann","year":"2016","journal-title":"Gut"},{"issue":"11","key":"pmed.1004842.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006653","article-title":"Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use","volume":"13","author":"BN Parsons","year":"2017","journal-title":"PLoS Pathog"},{"issue":"1","key":"pmed.1004842.ref025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jcmgh.2017.03.004","article-title":"Gastrin and gastric cancer","volume":"4","author":"JP Smith","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"pmed.1004842.ref026","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000199381","article-title":"Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion","author":"N Havu","year":"1986","journal-title":"Digestion"},{"issue":"6","key":"pmed.1004842.ref027","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/apt.13324","article-title":"Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology","volume":"42","author":"L Lundell","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"pmed.1004842.ref028","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"MF Vaezi","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"pmed.1004842.ref029","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1053\/j.gastro.2007.06.014","article-title":"Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study","volume":"133","author":"DJ Robertson","year":"2007","journal-title":"Gastroenterology"},{"issue":"9","key":"pmed.1004842.ref030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/2042098617715381","article-title":"Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence","volume":"8","author":"ML Maes","year":"2017","journal-title":"Ther Adv Drug Saf"},{"issue":"8","key":"pmed.1004842.ref031","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1136\/gutjnl-2018-316958","article-title":"Proton pump inhibitors and gastric cancer: association is not causation","volume":"68","author":"P Moayyedi","year":"2019","journal-title":"Gut"},{"issue":"3","key":"pmed.1004842.ref032","article-title":"PPIs and gastric cancer: any causal relationship?","volume":"94","author":"P Crafa","year":"2023","journal-title":"Acta Biomed"},{"key":"pmed.1004842.ref033","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067873","article-title":"Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study","volume":"375","author":"A Israel","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"pmed.1004842.ref034","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMc2406156","article-title":"Type 2 diabetes in patients with G6PD deficiency","volume":"391","author":"A Israel","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"pmed.1004842.ref035","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/ciad348","article-title":"Glucose-6-phosphate dehydrogenase deficiency and coronavirus disease 2019","volume":"77","author":"A Israel","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pmed.1004842.ref036","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJMoa001999","article-title":"Helicobacter pylori infection and the development of gastric cancer","volume":"345","author":"N Uemura","year":"2001","journal-title":"N Engl J Med"},{"key":"pmed.1004842.ref037","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(00)70004-7","article-title":"Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome","volume":"118","author":"MM Wolfe","year":"2000","journal-title":"Gastroenterology"},{"issue":"2","key":"pmed.1004842.ref038","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3892\/ijo.2012.1481","article-title":"Barrett\u2019s esophagus and esophageal cancer: an overview","volume":"41","author":"V Conteduca","year":"2012","journal-title":"Int J Oncol"},{"issue":"9","key":"pmed.1004842.ref039","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1007\/s00432-021-03544-3","article-title":"Do proton pump inhibitors prevent Barrett\u2019s esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis","volume":"147","author":"Y Chen","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"pmed.1004842.ref040","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/fmb.10.25","article-title":"Helicobacter pylori eradication therapy","volume":"5","author":"H Suzuki","year":"2010","journal-title":"Future Microbiol"},{"issue":"10","key":"pmed.1004842.ref041","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1093\/hmg\/ddv054","article-title":"Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour","volume":"24","author":"O Calvete","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"2","key":"pmed.1004842.ref042","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/osp4.475","article-title":"Body mass index trajectories among people with obesity and association with mortality: evidence from a large Israeli database","volume":"7","author":"O Reges","year":"2020","journal-title":"Obes Sci Pract"},{"issue":"2","key":"pmed.1004842.ref043","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12603-014-0016-4","article-title":"The associations between diet quality, Body Mass Index (BMI) and Health and Activity Limitation Index (HALex) in the Geisinger Rural Aging Study (GRAS)","volume":"18","author":"DW Ford","year":"2014","journal-title":"J Nutr Health Aging"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T18:23:51Z","timestamp":1767723831000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004842"}},"subtitle":[],"editor":[{"given":"Gilaad G.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004842","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]}}}